Patent · US Active

RNAS for complement inhibition

US12251395B2 · kind B2 · utility

0Cited by

12References

7Claims

0Family size

Assignee

Apellis Pharmaceuticals, Inc. · US

Inventors

Christian Mueller · Wiesbaden, DE
Lukas Scheibler · Laguna Beach, US

Key dates

Filing date	Sep 12, 2022
Grant date	Mar 18, 2025
Priority date	—
Expiry date	Sep 12, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14145
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.